The era of the development of the medical industry has come. There has been so much brimming in that industry that it is becoming difficult for people to realize that the world is developing at a very fastened rate. Therefore, the risk of cardiovascular disease is also increasing for people with the changing times. Therefore, the era of customized medications has now come. There have been various studies that have been conducted for the same and hence, an attempt is made to ensure that the studies are conducted to ensure the proximity extension and study 587 proteins that are available in the body of the persons. The predictive value of the protein panel was confirmed superior to the clinical risk model which has been in practice since the times immemorial. Therefore, in the initial prevention setting, a proteome-based model outperforms a model comprising clinical risk factors in predicting the risk of CV events.
Ref art: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa648/5893663
